Gastroesophageal Reflux Disease (GERD) is a commonly encountered condition in clinical practice. It is characterized by the frequent occurrence of heartburn due to the backflow of stomach acid into the esophagus. This article aims to provide a comprehensive guide to the diagnosis and treatment of GERD for healthcare professionals.
The diagnosis of GERD is primarily based on the patient's clinical history. The presence of typical symptoms such as heartburn, regurgitation, and dysphagia is indicative. However, in cases where symptoms are atypical, further diagnostic procedures may be necessary. Upper endoscopy is recommended for patients with alarm symptoms such as weight loss, anemia, or dysphagia. Ambulatory pH or impedance monitoring is the gold standard for diagnosing GERD, particularly in patients with non-cardiac chest pain or refractory symptoms.
The treatment of GERD involves lifestyle modifications, pharmacological therapy, and in some cases, surgical intervention. Lifestyle modifications include weight loss, elevating the head of the bed, and avoiding meals close to bedtime. Pharmacological therapy primarily involves proton pump inhibitors (PPIs), which are effective in healing erosive esophagitis and relieving GERD symptoms. However, long-term use of PPIs should be approached with caution due to potential side effects. Surgical intervention, such as fundoplication, is considered for patients with refractory symptoms or complications of GERD.
GERD is a prevalent condition with significant impact on quality of life. Accurate diagnosis and effective treatment are crucial to manage this condition. Healthcare professionals should be well-versed in the diagnostic procedures and treatment options for GERD to provide optimal patient care.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation